206 related articles for article (PubMed ID: 8603408)
1. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
Okada K; Nannmark U; Vujanovic NL; Watkins S; Basse P; Herberman RB; Whiteside TL
Cancer Res; 1996 Apr; 56(7):1599-608. PubMed ID: 8603408
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
4. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
5. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
7. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
Nannmark U; Hokland ME; Agger R; Christiansen M; Kjaergaard J; Goldfarb RH; Bagge U; Unger M; Johansson BR; Albertsson PA; Basse PH
In Vivo; 2000; 14(5):651-8. PubMed ID: 11125549
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
9. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles.
Goldfarb RH; Kitson RP; Brunson KW; Yoshino K; Hirota N; Kirii Y; Kotera Y; Inoue Y; Ohashi M
Anticancer Res; 1999; 19(3A):1663-7. PubMed ID: 10470098
[TBL] [Abstract][Full Text] [Related]
11. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
13. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
14. Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.
Quintieri L; Rosato A; Amboldi N; Vizler C; Ballinari D; Zanovello P; Collavo D
Br J Cancer; 1999 Mar; 79(7-8):1067-73. PubMed ID: 10098738
[TBL] [Abstract][Full Text] [Related]
15. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
16. IL-12 cDNA direct injection: antimetastatic effect from a single injection in a murine hepatic metastases model.
Weber SM; Qi C; Neal Z; Sondel P; Mahvi DM
J Surg Res; 2004 Dec; 122(2):210-7. PubMed ID: 15555620
[TBL] [Abstract][Full Text] [Related]
17. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
[TBL] [Abstract][Full Text] [Related]
18. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.
Siders WM; Wright PW; Hixon JA; Alvord WG; Back TC; Wiltrout RH; Fenton RG
J Immunol; 1998 Jun; 160(11):5465-74. PubMed ID: 9605149
[TBL] [Abstract][Full Text] [Related]
19. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
20. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency.
Hill LL; Perussia B; McCue PA; Korngold R
Cancer Res; 1994 Feb; 54(3):763-70. PubMed ID: 8306339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
